Protocol Ledger

NCT03000439 · Phase III · COMPLETED

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Interventional Phase III clinical trial protocol NCT03000439 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-10 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03000439
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03000439
Protocol FieldVerified Registry Value
NCT IdentifierNCT03000439
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2018-05-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03000439
Hospital Research SiteLocationSite Profile
Phoenix Children's HospitalPhoenix, AZOpen Hospital Dossier ->
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI